
In the pursuit of health and recovery, rational use of drugs is a crucial part. Patients should be fully aware of the information about the drug, including but not limited to efficacy, dosage, and contraindications, before using any drug. Be sure to follow the doctor's guidance and do not increase or decrease the dose or change the drug at will, so as not to affect the efficacy or cause adverse reactions; Be aware of drug-drug interactions and avoid self-medication.
Cabozantinib has been approved for the treatment of various cancers.【more】
Article source:Captain MedicineRelease date:2026-01-06Recommended:272
Suitable for locally advanced or metastatic non-small cell lung cancer (NSCLC) patients with EGFRT790M mutation positivity.【more】
Article source:Captain MedicineRelease date:2026-01-06Recommended:64
Treat thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenic purpura.【more】
Article source:Captain MedicineRelease date:2026-01-06Recommended:275
Crizotinib is suitable for the treatment of non-small cell lung cancer.【more】
Article source:Captain MedicineRelease date:2026-01-06Recommended:207
Finerenone is applicable to chronic kidney disease related to type 2 diabetes.【more】
Article source:Captain MedicineRelease date:2026-01-06Recommended:264
Mitotane is used for treatment Adrenal cortex carcinoma.【more】
Article source:Captain MedicineRelease date:2026-01-06Recommended:264
Cibinqo can treat atopic dermatitis.【more】
Article source:Captain MedicineRelease date:2026-01-06Recommended:259
Broad-spectrum antitumor agents【more】
Article source:Captain MedicineRelease date:2026-01-05Recommended:260
KRAS G12C mutation in non-small cell lung cancer and colorectal cancer【more】
Article source:Captain MedicineRelease date:2026-01-05Recommended:260
The treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) patients.【more】
Article source:Captain MedicineRelease date:2026-01-05Recommended:190
Koselugo is suitable for treating children aged 2 years and above with type 1 neurofibromatosis.【more】
Article source:Captain MedicineRelease date:2026-01-05Recommended:269
Alpelisib combined with Fluvastatin in the treatment of postmenopausal women and men with breast cancer.【more】
Article source:Captain MedicineRelease date:2026-01-05Recommended:261
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended:8542025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended:10552024-09-07
Recently, Lao Lucius Pharmaceutical (Lucius Pharmaceuticals) issued a solemn statement regarding cou···【more】
Recommended:3462026-10-10
Lucius Pharmaceuticals Version of Vibegron Now Available1.Basic Drug InformationVibegron (generic na···【more】
Recommended:4202026-06-08
In recent years, leveraging the World Trade Organization (WTO) patent waiver for least-developed cou···【more】
Recommended:6192026-05-08
How Can Chinese Patients Access Generic Drugs from Laos?In recent years, generic drugs from Laos hav···【more】
Recommended:6052026-04-08
Lucius Pharmaceuticals version of Ibrutinib is now availableIn a randomized controlled trial of 269 ···【more】
Recommended:4752026-03-08
Leveraging the WTO patent waiver for least-developed countries (extended to 2033), Laos has seen rap···【more】
Recommended:6232026-31-07

Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address: No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com

Name: Lucius

Telegram name: Vira
No.:0085253923643
Telegram name: Vira
No.:0085253923643